-+ 0.00%
-+ 0.00%
-+ 0.00%

Immix Biopharma Surpasses 50% Enrollment In NEXICART-2 Trial For CAR-T NXC-201 In Relapsed/Refractory AL Amyloidosis, Advancing Toward BLA Submission

Benzinga·09/18/2025 17:32:55
Listen to the news

– On track for first FDA Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis –

Los Angeles, CA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that 50% enrollment milestone has already been surpassed in NEXICART-2, its relapsed/refractory AL Amyloidosis clinical trial of sterically-optimized CAR-T NXC-201. Immix continues to enroll expediently toward BLA submission.